The benefit from Memantine (Ebixa) is assessed by repeating the cognitive assessment at around 3 months. Such assessment cannot demonstrate how the disease may have progressed in the absence of treatment, but it can give a good guide to response. Up to half the patients given this class of drugs show a slower rate of cognitive decline.
Dosage for Memantine (Ebixa)
The usual dose of Memantine (Ebixa) is initially 5mg in the morning, increased in steps of 5mg at weekly intervals up to a max dose of 10mg twice daily; doses over 5mg should be given in 2 divided doses.
THE PRICES LISTED ARE FOR MEDICATION DISPENSED ON A PRIVATE PRESCRIPTION.
SOME PATIENTS,HOWEVER, MAY BE ELIGIBLE TO OBTAIN THIS MEDICATION ON AN NHS PRESCRIPTION. YOUR DOCTOR WILL BE ABLE TO ADVISE YOU WHICH TYPE OF PRESCRIPTION YOU REQUIRE.
Nice does not recommend Memantine (Ebixa) for moderately severe to severe Alzheimer’s disease except as part of well designed clinical studies; patients already receiving Memantine can continue treatment until they, their carers, or their specialist consider it appropriate to stop.
Further Information about Ebixa
For more information about the dosage and side-effects of Ebixa, click here to download the Patient Information Leaflet from the Electronic Medicines Compendium.